Scientists probe why lung disease raises COVID-19 risk
NCT ID NCT04444609
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study investigates how the immune system responds to COVID-19 in people with chronic lung conditions like asthma, COPD, or cystic fibrosis, compared to those without lung disease. Researchers collect blood, sputum, and nasal samples to measure immune signals and gene activity. The goal is to uncover why some patients develop severe illness, which could guide future treatments or vaccines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why people with lung disease are more vulnerable to severe COVID-19, pointing toward better prevention or treatment strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Brompton & Harefileld NHS Trusts
London, London, SW3 6PP, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may foresee lung complications after liver surgery
- Can paxlovid be safely used in pregnancy? a new trial investigates
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?